Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MapLight TherapeuticsMPLT -0.64%12 Cash-to-Debt is 153.36 as of Jun. 2026, which is 546% above its 10-year median of 23.75. GuruFocus rates MPLT with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,393 Biotechnology companies, MapLight Therapeutics ranks better than 79.47% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MapLight Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 153.36.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, MapLight Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for MapLight Therapeutics's Cash-to-Debt or its related term are showing as below:
MPLT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 4.41 Med: 23.75 Max: 153.36
Current: 153.36
During the past 4 years, MapLight Therapeutics's highest Cash to Debt Ratio was 153.36. The lowest was 4.41. And the median was 23.75.
MPLT's Cash-to-Debt is ranked better than 79.47% of 1393
companies
in the Biotechnology industry
Industry Median: 7.03
vs MPLT: 153.36
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
MapLight Therapeutics Cash-to-Debt Related Terms
MapLight Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for MapLight Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, MapLight Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MapLight Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MapLight Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where MapLight Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MapLight Therapeutics (MPLT) has a Cash-to-Debt of 153.36 as of Jun. 2026. This is 546% above median its historical median of 23.75. Over the past decade, MapLight Therapeutics' Cash-to-Debt has ranged from 4.41 to 153.36. According to the industry distribution chart, MapLight Therapeutics ranks #286 out of 1393 companies in the Biotechnology industry, placing it in the top 20.5%.
Is MapLight Therapeutics' Cash-to-Debt too high?
MapLight Therapeutics' current Cash-to-Debt of 153.36 is 546% above median its 10-year median of 23.75. Over the past 10 years, this metric has ranged from a low of 4.41 to a high of 153.36. The Biotechnology industry median Cash-to-Debt is 7.03. MapLight Therapeutics' value of 153.36 is 2081.5% above this industry median. Based on the distribution chart, MapLight Therapeutics ranks #286 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MapLight Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' Cash-to-Debt compare to SPRY and EIKN?
According to the Biotechnology industry distribution chart, MapLight Therapeutics ranks #286 out of 1393 companies for Cash-to-Debt. This places MapLight Therapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 7.03. MapLight Therapeutics' value of 153.36 is 2081.5% above this benchmark. Historically, MapLight Therapeutics' own Cash-to-Debt has ranged from 4.41 to 153.36 over the past decade. While the company's 10-year median is 23.75 vs. the industry median of 7.03, MapLight Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MapLight Therapeutics's current Cash-to-Debt of 153.36 is 2081.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MapLight Therapeutics's current Cash-to-Debt is 153.36, which is 546% above median its own 10-year median of 23.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current Cash-to-Debt of 153.36. The current Cash-to-Debt is 153.36, which is 546% above median its 10-year median of 23.75 and 2081.5% above the Biotechnology industry median of 7.03. MapLight Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current Cash-to-Debt is 153.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MapLight Therapeutics Inc. is a clinical-stage biopharmaceutical company based in the United States that develops therapies for central nervous system disorders. The company's discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, with the goal of improving efficacy, safety, tolerability, and ease of use. Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis; the design aims to activate central receptors while mitigating peripheral side effects. MapLight was founded by leaders in psychiatry and neuroscience research to address the shortage of circuit-specific pharmacotherapies. As a clinical-stage company, it does not yet market approved products and depends on equity financing and partnership or licensing arrangements to fund research and development.
12GF Score
Get the complete analysis for MPLT
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MPLT has been successfully added to your 
